Center-Authored Papers

Filters: Author is Gilbert, Peter B  [Clear All Filters]
2008
Yang Y, Gilbert PB, Longini IM, Halloran ME.  2008.  A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.. The annals of applied statistics. 2(4):1409-1431. Abstract
Gilbert PB, Hudgens MG.  2008.  Evaluating candidate principal surrogate endpoints.. Biometrics. 64(4):1146-54. Abstract
Sun Y, Hyun S, Gilbert PB.  2008.  Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment.. Biometrics. 64(4):1070-9. Abstract
Li Z, Gilbert PB, Nan B.  2008.  Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.. Biometrics. 64(4):1247-55. Abstract
Qin L, Gilbert PB, Follmann D, Li D.  2008.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.. The annals of applied statistics. 2(1):386-407. Abstract
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
Gilbert PB, Qin L, Self SG.  2008.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.. Statistics in medicine. 27(23):4758-78. Abstract
2009
Kittikraisak W, van Griensven F, Martin M, McNicholl J, Gilbert PB, Chuachoowong R, Vanichseni S, Sutthent R, Tappero JW, Mastro TD et al..  2009.  Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand.. Journal of acquired immune deficiency syndromes (1999). 51(5):601-8. Abstract
Hudgens MG, Gilbert PB, Mascola JR, Wu C-D, Barouch DH, Self SG.  2009.  Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.. The Journal of infectious diseases. 200(4):609-13. Abstract
Hudgens MG, Gilbert PB.  2009.  Assessing vaccine effects in repeated low-dose challenge experiments.. Biometrics. 65(4):1223-32. Abstract
Sun Y, Gilbert PB, McKeague IW.  2009.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.. Annals of statistics. 37(1):394-426. Abstract
Huang Y, Gilbert PB, Montefiori DC, Self SG.  2009.  Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.. Statistics in biopharmaceutical research. 1(1):81-91. Abstract
Jones NG, DeCamp A, Gilbert PB, Peterson ML, Gurwith M, Cao H.  2009.  AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.. Vaccine. 27(7):1136-40. Abstract
Gilbert PB, Qin L, Self SG.  2009.  Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.. Statistics in medicine. 28(4):716-9.
Gilbert PB, Sato A, Sun X, Mehrotra DV.  2009.  Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.. Vaccine. 27(3):396-401. Abstract
Wick DW, Gilbert PB, Yang OO.  2009.  Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo.. Journal of virology. 83(5):2349-56. Abstract
Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B et al..  2009.  Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.. Journal of virology. 83(17):8925-37. Abstract
2010
Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester WC, Ogwu A et al..  2010.  HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.. PloS one. 5(4):e10148. Abstract
Gilbert PB, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M et al..  2010.  Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.. The Journal of infectious diseases. 202(4):595-605. Abstract
Wolfson J, Gilbert PB.  2010.  Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.. Biometrics. 66(4):1153-61. Abstract
Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG et al..  2010.  Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.. Journal of virology. 84(3):1439-52. Abstract
Gilbert PB, Jin Y.  2010.  Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data.. Biostatistics (Oxford, England). 11(1):34-47. Abstract
Zhang M, Gilbert PB.  2010.  Increasing the Efficiency of Prevention Trials by Incorporating Baseline Covariates.. Statistical communications in infectious diseases. 2(1) Abstract
Gilbert PB.  2010.  Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts.. Statistics in medicine. 29(10):1061-71. Abstract
2011
Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG.  2011.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.. The Journal of infectious diseases. 203(7):969-75. Abstract